ABSTRAK
Acute lymphoblastic leukemia (ALL) is the most common type of childhood leukemia which accounts for 75-80% of all cases. 1 From 2007 to 2012, there were 1,957 cases from 15 referral hospitals in Indonesia. 2 In Cipto Mangunkusumo Hospital (CMH), Jakarta, there were 579 cases during 2007-2013 with approximately 80 new cases each year. 3, 4 The event free survival (EFS) rates in developed countries is 80-90% but it is very different in developing countries. 5 Gatot and Windiastuti 3 reported EFS rates of 53% from ALL patients in CMH from 1998-2004, 53% while Mulatsih et al 6 reported that in Dr. Sardjito Hospital, Yogyakarta, Indonesia, the EFS rates were 53%. A high relapse rate in ALL is also another major problem. Windiastuti 7 found that relapse rates in CMH was 29%, almost three times higher compared to developed countries. These differences can be attributed to numerous factors, such as early detection, referral system, diagnostic tools, treatment choice, remission monitoring, nutritional status, evaluation of side effect from chemotherapy, and supportive facilities which in turn influences the treatment outcome.
5
Risk stratification in developing countries is based on the National Cancer Institute (NCI) criteria; age 1-0 years old and leukocyte count <50,000 /µL. 8 Pediatric Hematology Oncology Division, Child Health Department, Faculty of Medicine Universitas Indonesia (FMUI-CMH) is using the following criteria; age, leukocyte count, mediatinal mass, and central nervous system (CNS) infiltration. This criteria stratifies ALL patients into high risk or standard risk. 7 Meanwhile, developed countries are already using molecular risk stratification for ALL patients.
Molecular assessment shows that certain fusion gene plays a role in leukemic cell proliferation and differentiation, affect the clinical characteristics and now becomes one of important prognostic factors. Some important fusion genes of leukemia are TEL-AML1, BCR-ABL, MLL-AF4, E2A-PBX1 in B-cell ALL.
9 Patient with TEL-AML1 has an excellent prognosis with EFS rates of approximately 90%, regardless age and leukocyte count. 10 Infant <1 year old was originally categorized as high risk based on NCI criteria, but studies have found that if there is no MLL-AF4 gene changes, the prognosis is similar to those aged >1 year. 11 Fusion gene BCR-ABL and MLL-AF4 are related to cytostatic drug resistence including steroid.
12 E2A-PBX1 needs intensive chemotherapy to reach good EFS. This indicates the importance of genetic factors in determining prognosis. Based on fusion gene, molecular stratification can be divided into three categories; high risk (BCR-ABL and MLL-AF4), intermediate risk (E2A-PBX1) and standard risk (TEL-AML1).
Reduction or clearance of peripheral blast after one week steroid administration is known as a significant prognostic factor to predict treatment outcome. 13 Good response is defined as a blast count of <1,000 /µL and has 2-3 times better prognosis compared to poor response, defined as a blast count of ≥1,000 /µL.
14 This assessment is easy, inexpensive, and can be used in centres in Indonesia. Moreover, it is significant in predicting prognosis and has yet to be routinely performed in Indonesia. The aim of this study was to evaluate if steroid response at day-eight has a significant correlation with molecular assessment as the gold standard.
METHODS
A comparative cross sectional study was performed at CMH from January 2013 to March 2014. A total of 73 patients were enrolled. Inclusion criteria were newly diagnosed ALL children (age 0-18 year old). Patients were excluded from this study if they had ALL L 3 subtype and Down syndrome. Bone marrow aspiration was performed for molecular assessment. Patients were given steroid and the response was evaluated at day eight. The protocol for the present study was approved by the Ethics Committee of Faculty of Medicine Universitas Indonesia/Cipto Mangunkusumo Hospital (No.
594/H2.F1/ETIK/2013).

Clinical laboratory parameters
Hematology parameters, peripheral blast count, and immunophenotyping were examined in Clinical Pathology Department CMH, and Dharmais Cancer Hospital.
Molecular assessment
Molecular assessment was performed using nested-polymerase chain reaction (nested-PCR) method in Integrated Laboratory, Faculty of Medicine Universitas Indonesia (FMUI). The fusion genes examined were TEL-AML, BCR-ABL, E2A-PBX1, and MLL-AF4. Cell line for each 
Statistical analysis
The data was analysed using statistical package for social sciences (SPSS) version 20.0. Chisquare or fisher exact test were done as appropriate to compare between good and poor response.
RESULTS
Due to sampling quantity, molecular assessment was only performed in 52 of 73 patients. From them, the fusion gene was only detected in 45 patients. Table one shows the initial clinical and laboratory characteristics of both groups of patients. The mean age was 3.5 years with the number of male patients 29/45 (66%) being almost two times that of female patients. This research found 26/32 (81%) of patients aged one to <10 years old were good responders, while 3/4 (75%) of patient <1 year old and 7/9 (78%) patient aged ≥10 years old were poor responders. Age had significant influence on steroid response (fisher exact test, p=<0.001). Pallor, fever, bone pain, bleeding, limphadenopathy, hepatomegaly, and splenomegaly as common presenting features were more prominent in poor response group. Mediastinal mass was only found in four patients, and 3/4 (75%) of them in poor response group. None of patients presented with testis or CNS infiltration.
The mean value for hemoglobin was 8.4 g/dL, platelet was 40,217 /µL, and leukocyte was 72,036 /µL. Most patients 36/45 (80%) with leukocyte count <50,000 /µL. All patients (100%) with leukocyte count between 50,000-100,000/µL were good responses while 5/7 (71%) patients with leukocyte count >100,000/µL were poor responses, which showed leukocyte count as significant factor to steroid response (fisher exact test, p<0.05).
Based on morphology, 40/45 (89%) subjects had L 1 type and 5/45 (11%) had L 2 type. Immunophenotyping showed 34 subjects (76%) with B-cell and only three subjects (7%) with mixed cell. There were eight subjects (27%) with T-cell, and seven of them (88%) showed poor steroid response while 74% of B-cell and 100% of mixed-cell showed good steroid response. Statistical analysis showed that ALL cell had significant correlation with steroid response (fisher exact test, p<0.05).
Molecular assessment showed that the most common fusion gene in this study was E2A-PBX1 19/45 (42%), followed by TEL-AML1 17/45 (38%), BCR-ABL 5/45 (17%), and MLL-AF4 1/45 (3%). From all response, 13/17 (77%) patients with TEL-AML1 and 12/19 (63%) patients with E2A-PBX1 showed good steroid response while 4/5 (80%) patients with BCR-ABL and all patients with MLL-AF4 fusion gene showed poor steroid response.
In this study, fusion gene TEL-AML1 was stratified into standard risk group while BCR-ABL, MLL-AF4, and E2A-PBX1 were stratified into high risk group. Table 2 showed that 25% patients from standard risk group of molecular had poor steroid response. Otherwise, there were 55% patients from high risk group with good steroid response. Statistical analysis showed that steroid response has no correlation with molecular assessment (p>0.05).
DISCUSSION
The mean age of patients in this study was 3.5 years, similar to what has been reported in literature that the peak incidence of childhood ALL is between the ages of two to five years old. 15 The age distribution was similar with previous study in Oman that found 13% childhood ALL patient were aged <1 year, 77% were aged between one to 10 years, and 11% were aged >10 years. 16 In this study, 81% of patient aged one to <10 years old had good response, while 75% of patient <1 year old and 78% patient aged ≥10 years old had poor response. Age is known as an important prognostic factor, with many studies showing that patient aged <1 and >9 years old had poor prognosis. This is related to certain Table 2 . Association between steroid response and molecular assessment http://mji.ui.ac.id genetic abnormalitites. MLL fusion gene is more common in patient aged <1 year old and BCR-ABL in patient aged >9 years old. TEL-AML1 is related with good prognosis and commonly found in ALL children aged between one to nine years. 17, 18 This study found that ALL incidence in male were almost two times higher than female (64% vs 36%), similar with many previous studies in Myanmar, 17 Oman, 16 Argentina, 13 and Pakistan. 18 Pallor, fever, bone pain, bleeding, lymphadenopathy, hepatomegaly, and splenomegaly as main clinical symptoms in ALL were more prominent in poor responders. Testicular and CNS infiltration as early clinical sign were very rare. Yasmeen and Ashraf 18 found only 2% of ALL patients presented with testicular infiltration and 5% with CNS infiltration. Felice, et al found 1-3% patient with CNS infiltration and no testicular infiltration. 13 In this study, there were no patients that presented with testicular or CNS infiltration.
There were four patients (13%) with mediastinal mass, Pui 19 found 10%-18% of patient presented with mediastinal mass. Three of four patients (75%) were poor responders. Many studies found that mediastinal mass is a poor prognosis factor that related to thymus hyperplasia and resulter in T-cell. Clinically, T-cell was correlated with high leucocyte count and high incidence of relaps and CNS infiltration. 20 This study found that most patient (75%) with leukocyte count <50,000 /µL and all patient (100%) with leukocyte count between 50,000-100,000 / µL were good responders, while 71.4% patient with leukocyte count >100,000 /µL were poor responders. High leukocyte count is related with poor prognosis and need more intensive therapy. 21 Morphology examination from bone marrow aspiration showed that L 1 type (88.9%) was more common than L 2 type (11.1%). These results were similar with Mulatsih, et al 6 who found 70% L 1 and 30% L 2 and also Onciu and Pui 1 who found 82% L 1 and 15% L 2 . Immunophenotyping assessment showed B-cell as most common ALL type (76%), followed by T-cell 27% and mixed cell 7%. This result was quite similiar with Supriyadi et al 22 who found 63% patient with B-cell, 67% with T-cell and only 0.2% with mixed cell. From all eight patients with T-cell, seven of them (88%) showed poor steroid response. Felice et al 13 found 80% patient with T-cell were poor responders. Clinically, T-cell is correlated with age >9 years, leukocyte count >50,000 /µL, mediastinal mass, CNS infiltration, and more common in male, which all lead to poor prognosis.
Fusion gene detection showed that E2A-PBX1 was the highest percentage (42%), followed by TEL-AML1 (38%), BCR-ABL (17%), and MLL-AF4 (3%). This result is different with Mulatsih et al 6 who found TEL-AML1 as the most common (23%), followed by BCR-ABL (11%), E2A-PBX1 (9%), no patient with MLL-AF4, and 57% patients without fusion gene. Pui 19 also found that TEL-AML1 was the most common fusion gene both in white and black children (19% and 13%), followed by E2A-PBX1 (11%) in black children.
Many studies found that BCR-ABL and MLL-AF4 fusion gene are related to high leukocyte count and steroid resistence. 12 In this study, 80% patient with BCR-ABL and 100% patient with MLL-AF4 fusion gene had poor steroid response. Meanwhile, 63% patient with E2A-PBX1 fusion gene showed good steroid response. Although E2A-PBX1 fusion gene was initially reported as poor prognostic factor, the cure rates is increasing with the use of more intensive chemotherapy such as high dose methotrexate. 12 It is already known that TEL-AML1 fusion gene has good prognosis with high EFS rate of approximately 90%.
12, 23 Borkhardt et al 24 found that this fusion gene were more common in female, aged one to five years, and without hyperleukocytosis. In this study, 77% patients with TEL-AML1 had good steroid response. Similar findings were found in a study by Uckun et al 25 where 84.0% patients with TEL-AML1 showed good response, directly related to its sensitivity to steroid. 25 In conclusion, age, leukocyte count, and immunophenotyping were all correlated with steroid response. Although some of fusion gene did show an implication in patient's steroid response, but there is no significant correlation with molecular assessment statistically.
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